A bsAb binding both HER2 and PRLR was conjugated to DM1 using a non-cleavable linker and showed superior in vitro activity compared to an “in house” generated HER2-DM1 ADC in breast cancer cell lines expressing both receptors [103]. Here, PRLR is linked to breast cancer.